ZME Science
No Result
View All Result
ZME Science
No Result
View All Result
ZME Science

Home → Science

Therapeutic vaccine shows promise of treatment against HPV infections that lead to cancer

A new vaccine might one-day replace surgery for cervical cancer.

Melvin SanicasbyMelvin Sanicas
April 24, 2019
in Science
A A
Share on FacebookShare on TwitterSubmit to Reddit

The human papillomavirus (HPV) infection has emerged as a major focus for the development of immunotherapeutic vaccines. Persistent infection with the virus causes at least six cancers or cancer precursors, with cervical cancer accounting for 80% of the worldwide burden of HPV-related cancers.

About 30 HPV types are spread through genital contact. Each is “named” with a number, in the order of their discovery. In addition, they are divided into two groups: There are about 12 types of HPV that are called “low risk” because they cannot cause cervical cancer. They can, however, cause genital warts or very minor cell changes on the cervix. These low-risk types of HPV are known by the numbers 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73 and 81. Types 6 and 11 – which are linked to about 90 percent of genital warts – are the most common. There are more than a dozen types of “high-risk” HPV that can cause abnormal cells to form on the cervix. These abnormal cell changes may gradually develop into cervical cancer if not removed. The 13 high-risk HPV types are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Types 16 and 18 are the most dangerous, since they cause about 70 percent of cervical cancers.

The therapeutic vaccine injects a specific protein that triggers the immune system to attack high-risk HPV types that cause nearly all cervical cancer precursors, known as cervical intraepithelial neoplasia or CIN. Cervical precancerous lesions are divided into three grades of severity: CIN 1 lesions generally clear up on their own. CIN 2 lesions can resolve on their own, but can also progress to CIN 3 lesions. CIN 3 is the most severe. It’s a slow-growing disease and fewer than half of CIN 3 lesions will develop into cancer in 20 – 30 years. While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing CIN grade 2 or 3.

The new study published in Gynecologic Oncology is a major step forward in efforts to prevent the progression of HPV-positive cervical lesions to cervical cancer and to reduce the treatment burden for the lesions. Women 18 years and older who had confirmed CIN2/3 were enrolled in a randomized, double-blind, placebo-controlled phase II trial and assigned to the vaccine candidate in a 2:1 ratio (vaccine : placebo). Overall, the subcutaneously administered vaccine led to clearance of precancerous cervical lesions was significantly higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 HPV types assayed (24% vs. 10%, p < 0.05). The candidate vaccine also cleared CIN 3 lesions regardless of HPV type (21% vs. 0%, p < 0.01). Subgroup analyses consistently showed clearance rates two to three times higher with the vaccine, irrespective of HPV type or lesion severity.  The vaccine was well tolerated with the most common adverse events being injection site reactions.

RelatedPosts

Promising new vaccine technology might finally end HIV-AIDS
When a Vital Cancer Therapy Relies on a Reliable Test, the Details Matter
Can you spread COVID-19 after getting vaccinated?
Moderna’s cancer vaccine shows strong test results and could be available by 2025

“Women who are afraid of having any kind of surgery, who haven’t had any children yet, who don’t want to have a surgical procedure, would be very excited about an option of having three shots, getting rid of their disease, and then not having to have surgery,” said Dr. Diane M. Harper, lead author and Professor of Obstetrics and Gynecology, University of Missouri Kansas City.

Surgery, which has a high cure rate, remains the cornerstone of therapy for cervical cancer but is associated with a risk of reproductive morbidity. A clear need exists for nonsurgical, non-ablative therapeutic options to treat HPV-associated diseases, the authors continued. Current screening strategies for HPV-associated diseases do not have any therapeutic option for women with persistent infection, which carries an unknown risk of progressing to cancer.

This study is the largest study to date following women for the longest time frame trialing a therapeutic vaccine for HPV associated CIN 2/3.

Tags: cancercervical cancerHPVvaccine

ShareTweetShare
Melvin Sanicas

Melvin Sanicas

Melvin is a curious lifelong learner. He studied biology, medicine, health economics, infectious diseases, clinical development, and public policy. He writes about global health, vaccines, outbreaks, and pathogens.

Related Posts

A unique eye accessory
Health

Miracle surgery: Doctors remove a hard-to-reach spinal tumor through the eye of a patient

byRupendra Brahambhatt
2 weeks ago
Health

This Futuristic Laser Blood Test May Be the Key to Beating Cancer Early

byTudor Tarita
1 month ago
Health

CT Scans Save Lives But Researchers Now Say They Could Also Be Behind 100,000 Future Cancer Cases

byTibi Puiu
1 month ago
Health

Scientists uncover how aspirin may help stop cancer from spreading

byAlexandra Gerea
2 months ago

Recent news

The Worm That Outsourced Locomotion to Its (Many) Butts

May 16, 2025

The unusual world of Roman Collegia — or how to start a company in Ancient Rome

May 16, 2025
Merton College, University of Oxford. Located in Oxford, Oxfordshire, England, UK. Original public domain image from Wikimedia Commons

For over 500 years, Oxford graduates pledged to hate Henry Symeonis. So, who is he?

May 16, 2025
  • About
  • Advertise
  • Editorial Policy
  • Privacy Policy and Terms of Use
  • How we review products
  • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Science News
  • Environment
  • Health
  • Space
  • Future
  • Features
    • Natural Sciences
    • Physics
      • Matter and Energy
      • Quantum Mechanics
      • Thermodynamics
    • Chemistry
      • Periodic Table
      • Applied Chemistry
      • Materials
      • Physical Chemistry
    • Biology
      • Anatomy
      • Biochemistry
      • Ecology
      • Genetics
      • Microbiology
      • Plants and Fungi
    • Geology and Paleontology
      • Planet Earth
      • Earth Dynamics
      • Rocks and Minerals
      • Volcanoes
      • Dinosaurs
      • Fossils
    • Animals
      • Mammals
      • Birds
      • Fish
      • Amphibians
      • Reptiles
      • Invertebrates
      • Pets
      • Conservation
      • Animal facts
    • Climate and Weather
      • Climate change
      • Weather and atmosphere
    • Health
      • Drugs
      • Diseases and Conditions
      • Human Body
      • Mind and Brain
      • Food and Nutrition
      • Wellness
    • History and Humanities
      • Anthropology
      • Archaeology
      • History
      • Economics
      • People
      • Sociology
    • Space & Astronomy
      • The Solar System
      • Sun
      • The Moon
      • Planets
      • Asteroids, meteors & comets
      • Astronomy
      • Astrophysics
      • Cosmology
      • Exoplanets & Alien Life
      • Spaceflight and Exploration
    • Technology
      • Computer Science & IT
      • Engineering
      • Inventions
      • Sustainability
      • Renewable Energy
      • Green Living
    • Culture
    • Resources
  • Videos
  • Reviews
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Editorial policy
    • Privacy Policy
    • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.